drugset / Trial / NCT00814060
Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)
RandomizedCrossoverOpen-labelTreatment
Summary
This study will examine the bioavailability (the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action) of two tablet formulations of Neratinib (HKI-272) compared to the capsule formulation.
Timeline
- Start
- 2009-01
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neratinib | Small molecule | 40 mg | — |
| Subject | Neratinib | Small molecule | 80 mg | — |
| Subject | Neratinib | Small molecule | 240 mg | — |
Indications
No indication recorded.